文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Sepsis-3时代的死亡率:多中心随机对照试验的系统评价

Mortality in the Sepsis-3 Era: A Systematic Review of Multicenter Randomized Controlled Trials.
PubMed 文献 · Shock · 2025-09-09
一句话结论Sepsis-3时代31项多中心随机对照试验中仅4项显示死亡率获益,多数药物和机制性干预未能降低死亡率。

该系统评价纳入2016年以来采用Sepsis-3标准、以死亡率作为主要或次要结局的成人脓毒症或脓毒性休克多中心随机对照试验。共纳入31项试验,超过7000例患者,覆盖550个中心。仅4项试验显示死亡率获益:3项来自中国(2项评价中药抗炎化合物,1项评价氨茶碱),1项来自欧洲(评价糖皮质激素治疗依赖血管加压药的脓毒性休克)。其余27项试验未报告死亡率获益。对照组中位死亡率为31.6%(四分位距24.1-45.5),干预组为35.4%(四分位距25.7-49.6)。

要点

  • Sepsis-3时代31项多中心随机对照试验中仅4项显示死亡率获益,其余27项未报告死亡率获益。
  • 显示死亡率获益的4项试验中,3项来自中国(2项中药抗炎化合物、1项氨茶碱),1项来自欧洲(糖皮质激素治疗依赖血管加压药的脓毒性休克)。
  • 对照组中位死亡率31.6%(四分位距24.1-45.5),干预组35.4%(四分位距25.7-49.6)。
  • 患者人群、脓毒症定义和结局报告存在显著异质性。
  • 未来研究应聚焦优化试验设计、细化患者选择和纳入死亡率以外的以患者为中心的结局。

适用人群与场景

  • 纳入标准:采用Sepsis-3标准诊断的成人脓毒症或脓毒性休克患者,且报告死亡率作为主要或次要结局。
  • 研究场景:多中心随机对照试验,共31项试验,超过7000例患者,覆盖550个中心。

研究设计与关键结果

  • 研究类型:系统评价,纳入2016年以来发表的多中心随机对照试验。
  • 样本量与中心数:31项试验,超过7000例患者,覆盖550个中心。
  • 主要结果:仅4项试验显示死亡率获益,其余27项试验未报告死亡率获益。
  • 死亡率获益试验构成:3项来自中国(2项评价中药抗炎化合物,1项评价氨茶碱),1项来自欧洲(评价糖皮质激素治疗依赖血管加压药的脓毒性休克)。
  • 对照组中位死亡率31.6%(四分位距24.1-45.5),干预组35.4%(四分位距25.7-49.6)。
  • 异质性:患者人群、脓毒症定义和结局报告存在显著异质性。

证据类型、等级与局限

  • 证据类型:系统评价。
  • 检索来源:Ovid MEDLINE、Embase、Cochrane Central、ClinicalTrials.gov、世界卫生组织ICTRP和Web of Science。
  • 数据提取:由两名独立评价者提取试验设计特征、资金来源、随机化方法和报告的结局。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该系统评价提示,Sepsis-3时代多数药物和机制性干预在多中心随机对照试验中未显示死亡率获益。
  • 作者认为未来研究应聚焦优化试验设计、细化患者选择和纳入死亡率以外的以患者为中心的结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

This systematic review examined multicenter randomized controlled trials conducted during the Sepsis-3 era that evaluated pharmaceutical and mechanistic interventions in adult patients with sepsis or septic shock, with a focus on identifying interventions that demonstrated mortality benefit. A comprehensive search was performed across Ovid MEDLINE, Embase, Cochrane Central, ClinicalTrials.gov, World Health Organization's ICTRP, and Web of Science for trials published since 2016. Studies were included if they enrolled adult patients with sepsis or septic shock using Sepsis-3 criteria and reported mortality as either a primary or secondary outcome. Data were extracted by two independent reviewers and included trial design characteristics, funding source, randomization methods, and reported outcomes. Among the 31 eligible multicenter randomized controlled trials enrolling over 7,000 patients across 550 centers, only four trials showed a mortality benefit. These included three studies from China-two evaluating herbal anti-inflammatory compounds and one evaluating aminophylline-and one European study assessing corticosteroid therapy in vasopressor-dependent septic shock. The remaining 27 trials reported no mortality benefit, and substantial heterogeneity was observed in patient populations, sepsis definitions, and outcome reporting. Median mortality in control arms was 31.6% (interquartile range 24.1-45.5), and 35.4% (interquartile range 25.7-49.6) in intervention arms. These findings suggest that despite extensive efforts, most interventions have not reduced mortality in multicenter sepsis trials. Future research should focus on optimizing trial design, refining patient selection, and incorporating patient-centered outcomes beyond mortality.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Nemet M, Karakus IS, Gmehlin CG, et al. Mortality in the Sepsis-3 Era: A Systematic Review of Multicenter Randomized Controlled Trials. Shock. 2025. PMID: 40997273. doi:10.1097/SHK.0000000000002687

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。